If there was a merger candidate which ever made sense in biotech and pharma it is Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). News from Bloomberg is out that the company has rejected an offer to…
Amylin Pharmaceuticals Inc. (NASDAQ: AMLN) and Eli Lilly & Co. (NYSE: LLY) are in the news on the diabetes front. The companies have announced that the European Commission has now approved its…
Jon C. Ogg AuthorDendreon Corp. (NASDAQ: DNDN), maker of prostate cancer drug Provenge, is once again rumored to be a takeover target. As Streetinsider.com points out, the company’s new chairman presided over the Eli Lilly…
By now, most investors know that the large hedge funds are run by billionaires rather than millionaires. What many investors might not know is that some hedge funds are reaching the size…
Indian drug maker Sun Pharmaceutical Industries Ltd. has received approval from the US Food and Drug Administration to sell its generic version of Zyprexa Zydis tablets in the the US. Eli Lilly…
Paul Ausick All three major indexes opened higher this morning, but the strength didn’t last as the Chicago PMI number failed to meet expectations and came in lower even than last month’s reading. The…
Drug maker Eli Lilly & Co. reported fourth quarter and full year earnings this morning, and although revenues were higher than expected, net income fell and EPS missed estimates. Lilly lost patent…
Paul Ausick Profits at Eli Lilly & Co. (NYSE: LLY) in 2012 will be sharply lower than analysts had been expecting. The drug maker, which lost patent protection on its best-selling anti-psychotic drug Zyprexa…
Paul Ausick Greece will announce its new government today. (Reuters) Inflation in China drops in October. (Reuters) Olympus investment losses may have gone above $1 billion. (Reuters) Silvio Berlusconi leaves as prime minister of…
Drug maker Eli Lilly & Co. (NYSE: LLY) reported third-quarter earnings this morning, and the company did a little better than analysts expected, but worries persist that the company will be hit…
Once patent protection expires on a prescription drug, the drug’s maker can take a serious beating in revenue and profitability. One way to make up for the loss is to get US…
Merck & Co. Inc. (NYSE: MRK) released second-quarter results last Friday and Pfizer Inc. (NYSE: PFE) reported this morning. The results of both drug behemoths are largely in line with analysts estimates…
Apple Inc (NASDAQ: AAPL) reported better than expected earnings and its shares soared (Reuters) Yahoo!’s (NASDAQ: YHOO) revenue fell (Reuters) A settlement of the debate over the U.S. debt pushed crude higher…
The number of stocks that made substantial gains for the week was limited. The great exception to that rule was Petrohawk Energy Corporation Co (NYSE: HK) which jumped 62.5% on Friday after…
Many drug companies face a what is called a patent cliff ahead, where the Big Pharma players will have key drugs go off-patent and there will be new generic competition. While this…
